Resources

The UK biotech financing numbers for Q3 are out, showing validation of UK assets but a sector under strain from prolonged global headwinds. Time to double down on investment in innovation as a driver for growth and deploy Industrial Strategy plans with urgency.

From scaling up advanced therapy manufacturing to harnessing the power of digital and automation, Ed Samuel, the new COO of the CGT Catapult, discusses how collaboration and innovation will shape the next phase of the UK’s cell and gene therapy ecosystem.

​​​​​​​Following a landmark TechBio Week, we reflect with some insights from our flagship conference on the transformative potential for growth of technological advances in the sector.

In this blog, Justin Wilson, Withers & Rogers LLP, shares his expert perspective on what the recent patent rulings from the Unified Patent Court (UPC) and the Court of Justice of the European Union (CJEU) mean in practice for biotech and pharma companies.

Find out about how opposition parties are positioning themselves in an increasingly fragmented political landscape, and what it might mean for our sector now and in the long term.

It’s TechBio week and we’re celebrating the UK’s leading role in AI and life sciences with significant investment and interest from global players and our own flagship TechBio UK conference and 2025 report launch. 

In this blog, NRG Therapeutics co-founder and CEO Dr Neil Miller and Parkinson’s UK Director of Research (and Investor Observer to NRG), Professor David Dexter, explore the history of the relationship and the innovation journey to date.

Maddy and Emma from BIA's policy and public affairs team report and reflect on the mood in Liverpool, and pull out the key insights for our sector.

Good to see support for BIA agendas in government messaging as we continue to push for pension fund reform, attracting the best global talent, UK manufacturing resilience and addressing the challenges of scaling.

In this blog, Tom Sheldon, Senior Manager at the Science Media Centre (SMC), explores how scientists and communicators are taking on misinformation head-on — and how the SMC’s work supports both researchers and journalists in helping the public make sense of complex, and sometimes controversial, scientific issues.

Ellie Avni, Senior Director in Employment Tax and Reward at FTI Consulting, explores how the new PISCES platform could reshape EMI and CSOP share option plans – creating fresh opportunities for flexibility and tax-efficient value realisation.

The BIA moves into a new era this week, amidst news from the US on tariffs for UK pharma, UK political party conferences underway and a change in leadership at GSK. It’s full steam ahead for BIA towards a busy Autumn, ensuring that the life science sector stays at the top of the government’s priority list and that our members are represented and connected.

Kirsty Neilson, Programme Manager at IBioIC, explains why she has just launched a new programme – Biotech Innovators: Train to Scale – offering a specialist business support programme for budding bioentrepreneurs.

This is my final CEO update in Newscast after 13 years at the BIA. I take up my new role as Executive Chair of the Office for Life Sciences next Monday. Before I do, I want to thank you - my loyal readers - for engaging with my musings over the years, and for your feedback that has improved this blog and my thinking.

This blog explores the key financial trends underpinning the UK's position in the mRNA revolution. The analysis, provided by Wendy Quainoo, the BIA’s Data Insights Executive, highlights the opportunities and challenges ahead, ensuring we can sustain the momentum needed to remain a global leader.

In this blog, Alan Griffith, Head of CDMO Global Operations, shares their achievements, priorities, and ambitions as a new member of the BIA community.

In this blog, Ivana Visnjic-Lynch, Marketing Manager at ZAGENO, discusses the race for breakthrough therapies and the need for  effective R&D spend management which enables technology to unlock the future.

In the last week, we have been hit by headlines that MSD plans to close its discovery research activities in London and that AstraZeneca is pausing investment due to the UK commercial environment and specifically in response to VPAG outcomes.

In this interview, we speak with Abby Clark, the BIA's Manufacturing Programme Manager, who shares her personal journey from a degree-level apprenticeship to a key policy role.

September has got off to a busy start at BIA, with significant raises, deals, expansion and M&A activity for members; welcoming our US counterparts to London, closely monitoring UK political shuffles and the party conference action as that kicks off with Reform and some unwelcome anti-vaccine misinformation.